Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Heska Co. stock logo
HSKA
Heska
$119.99
$119.09
$57.83
$120.03
$1.31B1.58241,932 shsN/A
IPSEN stock logo
IPSEY
IPSEN
$30.01
-0.5%
$29.30
$25.11
$32.25
$10.11B0.531,311 shs312 shs
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
$5.53
+4.1%
$5.20
$3.81
$29.30
$489.46M1.91.26 million shs1.43 million shs
Neogen Corporation stock logo
NEOG
Neogen
$5.08
+6.3%
$5.58
$3.87
$18.58
$1.04B1.773.46 million shs15.74 million shs
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
$9.88
+5.3%
$8.62
$5.90
$28.18
$971.61M2.212.94 million shs5.56 million shs
(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Heska Co. stock logo
HSKA
Heska
0.00%0.00%0.00%0.00%0.00%
IPSEN stock logo
IPSEY
IPSEN
+3.79%+4.00%+3.18%+6.39%-0.03%
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
+1.14%+9.26%+27.03%-39.93%-78.29%
Neogen Corporation stock logo
NEOG
Neogen
+1.06%+0.21%-19.26%-43.03%-69.42%
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
-1.88%+1.63%+34.19%+40.84%-58.09%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Heska Co. stock logo
HSKA
Heska
N/AN/AN/AN/AN/AN/AN/AN/A
IPSEN stock logo
IPSEY
IPSEN
N/AN/AN/AN/AN/AN/AN/AN/A
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
4.4531 of 5 stars
4.13.00.04.12.01.70.6
Neogen Corporation stock logo
NEOG
Neogen
3.8357 of 5 stars
3.34.00.00.01.13.32.5
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
4.6527 of 5 stars
4.33.00.04.71.42.50.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Heska Co. stock logo
HSKA
Heska
0.00
N/AN/AN/A
IPSEN stock logo
IPSEY
IPSEN
3.00
BuyN/AN/A
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
2.13
Hold$14.38160.12% Upside
Neogen Corporation stock logo
NEOG
Neogen
2.50
Moderate Buy$7.5047.64% Upside
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
2.65
Moderate Buy$33.37237.74% Upside

Current Analyst Ratings Breakdown

Latest NTLA, NEOG, MYGN, HSKA, and IPSEY Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/30/2025
Neogen Corporation stock logo
NEOG
Neogen
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$13.00 ➝ $10.00
6/16/2025
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral$7.00
6/16/2025
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$30.00
6/3/2025
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$74.00 ➝ $54.00
5/29/2025
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral$10.00 ➝ $7.00
5/29/2025
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$30.00
5/21/2025
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeSector Outperform ➝ Sector Perform$20.00 ➝ $6.00
5/20/2025
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$30.00 ➝ $30.00
5/19/2025
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral$10.00 ➝ $10.00
5/15/2025
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$12.50 ➝ $9.00
5/12/2025
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$55.00 ➝ $45.00
(Data available from 7/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Heska Co. stock logo
HSKA
Heska
$257.31M5.09$1.69 per share70.99$39.00 per share3.08
IPSEN stock logo
IPSEY
IPSEN
$3.87B2.60N/AN/AN/A
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
$837.60M0.61$1.04 per share5.31$7.70 per share0.72
Neogen Corporation stock logo
NEOG
Neogen
$924.22M1.19$1.09 per share4.66$14.52 per share0.35
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
$57.88M17.68N/AN/A$8.56 per share1.15
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Heska Co. stock logo
HSKA
Heska
-$19.89M-$1.93N/A83.33N/A-7.86%0.94%0.67%N/A
IPSEN stock logo
IPSEY
IPSEN
$374.30MN/A0.0010.42N/AN/AN/AN/A7/31/2025 (Estimated)
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
-$127.30M-$1.12N/AN/AN/A-12.20%-4.95%-3.39%8/5/2025 (Estimated)
Neogen Corporation stock logo
NEOG
Neogen
-$9.42M-$2.23N/A10.37N/A-53.56%2.69%1.82%7/29/2025 (Estimated)
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
-$519.02M-$5.23N/AN/AN/A-1,154.10%-56.06%-44.25%8/14/2025 (Estimated)

Latest NTLA, NEOG, MYGN, HSKA, and IPSEY Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
7/29/2025Q4 2025
Neogen Corporation stock logo
NEOG
Neogen
$0.09N/AN/AN/A$222.52 millionN/A
5/8/2025Q1 2025
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
-$1.26-$1.10+$0.16-$1.10$11.39 million$16.63 million
5/6/2025Q1 2025
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
-$0.05-$0.03+$0.02N/A$200.37 million$195.90 million
4/9/2025Q3 2025
Neogen Corporation stock logo
NEOG
Neogen
$0.12$0.10-$0.02-$0.05$225.27 million$221.00 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Heska Co. stock logo
HSKA
Heska
N/AN/AN/AN/AN/A
IPSEN stock logo
IPSEY
IPSEN
$0.260.87%N/AN/AN/A
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
N/AN/AN/AN/AN/A
Neogen Corporation stock logo
NEOG
Neogen
N/AN/AN/AN/AN/A
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
N/AN/AN/AN/AN/A

Latest NTLA, NEOG, MYGN, HSKA, and IPSEY Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
6/3/2025
IPSEN stock logo
IPSEY
IPSEN
$0.28960.97%6/9/20256/10/20256/25/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Heska Co. stock logo
HSKA
Heska
0.23
5.64
4.12
IPSEN stock logo
IPSEY
IPSEN
N/A
1.34
1.15
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
0.08
1.90
1.71
Neogen Corporation stock logo
NEOG
Neogen
0.33
3.91
2.45
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
N/A
4.90
4.90

Institutional Ownership

CompanyInstitutional Ownership
Heska Co. stock logo
HSKA
Heska
99.01%
IPSEN stock logo
IPSEY
IPSEN
N/A
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
99.02%
Neogen Corporation stock logo
NEOG
Neogen
96.73%
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
88.77%

Insider Ownership

CompanyInsider Ownership
Heska Co. stock logo
HSKA
Heska
12.30%
IPSEN stock logo
IPSEY
IPSEN
N/A
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
2.10%
Neogen Corporation stock logo
NEOG
Neogen
1.13%
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
3.10%
CompanyEmployeesShares OutstandingFree FloatOptionable
Heska Co. stock logo
HSKA
Heska
80810.91 million9.57 millionNot Optionable
IPSEN stock logo
IPSEY
IPSEN
5,325335.26 millionN/ANot Optionable
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
2,70092.18 million90.24 millionOptionable
Neogen Corporation stock logo
NEOG
Neogen
2,110217.04 million214.59 millionOptionable
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
600103.58 million100.37 millionOptionable

Recent News About These Companies

NTLA - Intellia Therapeutics Inc Chart - Morningstar
Intellia Therapeutics, Inc. (NTLA) - Yahoo Finance
NTLA Intellia Therapeutics, Inc. - Seeking Alpha
Brokers Issue Forecasts for NTLA FY2026 Earnings
Intellia Therapeutics Inc.

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Heska stock logo

Heska NASDAQ:HSKA

Heska Corporation manufactures and sells diagnostic and specialty products and solutions for veterinary practitioners in the United States, Canada, Mexico, Germany, Italy, Spain, France, Switzerland, Australia, and Malaysia. The company offers Element DC, Element DCX, Element DC5x veterinary chemistry analyzers for blood chemistry and electrolyte analysis; Element RC, Element RCX, and Element RC3X chemistry systems for blood chemistry and electrolyte analysis; Element HT5 and scil Vet abc Plus veterinary hematology analyzers to measure blood cell, platelet count, and hemoglobin levels; Element POC blood gas and electrolyte analyzers; Element i immunodiagnostic analyzers; and Element COAG and Element AIM veterinary analyzers. It also provides HeskaView Telecytology that provides in-clinic automated microscopic slide scanning and computing equipment; IV infusion pumps; digital radiography hardware and mobile digital radiography products; ultrasound systems; Cloudbank, a Web-based image storage solution; point-of-care products to detect antigens and antibodies associated with infectious and parasitic diseases of animals; Tri-Heart Plus chewable tablets for the treatment of canine heartworm infection, and ascarid and hookworm infections; and allergy products and services, including ALLERCEPT definitive allergen panels and therapy shots or drops. In addition, the company provides a line of bovine vaccines; biological and pharmaceutical products to other animal health companies; turnkey services comprising research, licensing, production, labeling, and packaging; and validation support and distribution services. It sells its products to veterinarians through a telephone sales force and third-party distributors; and trade shows, print advertising, and other distribution relationships. The company was formerly known as Paravax, Inc. and changed its name to Heska Corporation in 1995. The company was incorporated in 1988 and is based in Loveland, Colorado.

IPSEN stock logo

IPSEN OTCMKTS:IPSEY

$30.01 -0.14 (-0.46%)
As of 10:28 AM Eastern

Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial. The company also offers Somatuline, Decapeptyl, Cabometyx, Onivyde, Tazverik, and other oncology products; Dysport and other neurosciences products; and Bylvay, NutropinAq, Increlex, and Sohonos for rare diseases. The company was founded in 1929 and is based in Boulogne-Billancourt, France.

Myriad Genetics stock logo

Myriad Genetics NASDAQ:MYGN

$5.53 +0.22 (+4.14%)
Closing price 04:00 PM Eastern
Extended Trading
$5.44 -0.09 (-1.63%)
As of 07:06 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Myriad Genetics, Inc., a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. The company also offers Prolaris Prostate Cancer Prognostic Test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. It provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek, a non-invasive blood test that predicts the gender of a fetus; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, attention-deficit, hyperactivity disorder, and other mental health conditions. It has a strategic collaboration with Illumina, Inc., Memorial Sloan Kettering Cancer Center, the University of Texas MD Anderson Cancer Center, SimonMed, and Onsite Women's Health. Myriad Genetics, Inc. was incorporated in 1992 and is headquartered in Salt Lake City, Utah.

Neogen stock logo

Neogen NASDAQ:NEOG

$5.08 +0.30 (+6.28%)
Closing price 04:00 PM Eastern
Extended Trading
$5.15 +0.07 (+1.36%)
As of 06:47 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Neogen Corporation, together with its subsidiaries, engages in the development, manufacture, and marketing of various products and services dedicated to food and animal safety worldwide. It operates through two segments, Food Safety and Animal Safety. The Food Safety segment offers diagnostic test kits and related products to detect dangerous and unintended substances in food and animal feed, including foodborne pathogens, spoilage organisms, natural toxins, food allergens, genetic modifications, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns; and AccuPoint Advanced rapid sanitation test to detect the presence of adenosine triphosphate, a chemical found in living cells, as well as provides genomics-based diagnostic technology and software systems that help testers to objectively analyze and store their results and perform analysis on the results from multiple locations over extended periods. The segment offers its products primarily to milling and grain, meat and poultry, prepared foods and ingredients, fruits and vegetables, seafood, dairy, beverage, water, healthcare, traditional culture media markets, food service, and dietary supplements markets. The Animal Safety segment provides veterinary instruments, pharmaceuticals, vaccines, topicals, parasiticides, diagnostic products, rodent control products, cleaners, disinfectants, insect control products, and genomics testing services marketed through veterinarians, retailers, livestock producers, and animal health product distributors, for the animal safety market. The segment offers its products for companion animal veterinarians; livestock producers, veterinarians, and breed associations; retailers; breeding and genetics companies; diagnostic labs and universities; distributors; and other manufacturers and government agencies. Neogen Corporation was incorporated in 1981 and is headquartered in Lansing, Michigan.

Intellia Therapeutics stock logo

Intellia Therapeutics NASDAQ:NTLA

$9.88 +0.50 (+5.33%)
Closing price 04:00 PM Eastern
Extended Trading
$9.85 -0.03 (-0.30%)
As of 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, the company offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. It has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; and ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.